Key facts
- This page summarizes Vincent Capponi's Form 4 filing for Cytosorbents Corp (CTSO).
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 22 Jan 2025, 20:34.
Vincent Capponi - 17 Jan 2025 Form 4 Insider Report for Cytosorbents Corp (CTSO)
- Reporting relationship
- President and COO
- Issuer ticker
- CTSO
- Reported as of
- 17 Jan 2025
- Net transaction value
- +$31,760
- SEC form
- 4
- Accepted by SEC
- 22 Jan 2025, 20:34:26 UTC
- Prior SEC filing
- 08 Oct 2024
- Next SEC filing
- 26 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vincent Capponi
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Vincent Capponi filed Form 4 for Cytosorbents Corp (CTSO) on 22 Jan 2025.
Change
- Previous filing in this sequence was filed on 08 Oct 2024.
- Current net transaction value: +$31,760.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CTSO
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $31,760
- Shares
- +31,760
- Change %
- +5%
- Price
- $1.00
- Shares after
- 665,168
- Date
- 17 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CTSO
transaction
Derivative
Subscription Rights (right to buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $0
- Shares
- -31,760
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 17 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 31,760
- Exercise price
- $1.00
- Footnotes
- F1
CTSO
transaction
Derivative
Series A Right Warrants
Other
- Transaction value
- Shares
- +31,760
- Change %
- Price
- Shares after
- 31,760
- Date
- 17 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 31,760
- Exercise price
- Footnotes
- F1, F6, F7
CTSO
transaction
Derivative
Series B Right Warrants
Other
- Transaction value
- Shares
- +31,760
- Change %
- Price
- Shares after
- 31,760
- Date
- 17 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 31,760
- Exercise price
- Footnotes
- F1, F8, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the "Closing Date").
Footnote F2
Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of common stock, par value $0.001 per share (the "Common Stock"), of the Company upon vesting: 73,000 RSUs granted on July 7, 2023 and of which 24,334 RSUs remain unvested as of the date hereof;
Footnote F3
(continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;
Footnote F4
(continued from footnote 3) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 81,000 RSUs granted on April 2, 2024 and remain unvested as of the date hereof; and
Footnote F5
(continued from footnote 4) (iv) 352,834 shares of Common Stock owned by the reporting person.
Footnote F6
The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.
Footnote F7
The Series A Right Warrants expire 45 calendar days following the Closing Date.
Footnote F8
The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.
Footnote F9
The Series B Right Warrants expire 90 calendar days following the Closing Date.